Should You Buy Kenvue Stock After Its 30% Plunge?

Johnson & Johnson (NYSE: JNJ) spun off its consumer health unit as a separate entity in 2023. The new business, Kenvue (NYSE: KVUE), inherited a broad lineup of popular products, including Band-Aid adhesive bandages, Listerine mouthwash, Tylenol pain reliever, and Zyrtec allergy medicine. With an arsenal of household names in its lineup and a solid dividend, Kenvue seemed to be the kind of stock many income investors would love. However, this healthcare stock has delivered a decidedly disappointing performance since the spinoff two years ago. And it recently experienced another major sell-off. Should you buy Kenvue after its 30%+ plunge this year?Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool